Pirfenidone, a drug approved in October 2014, has been shown in two separate trials to significantly improve survival in patients with Idiopathic Pulmonary Fibrosis. Click here for the MedPage Today story.
Unknowingly disturbing asbestos during industrial or home renovation/retrofitting is resulting in the same disease consequences experienced by asbestos miners and insulators. The Center for Public Integrity relates a story of a young man with a very limited exposure to asbestos. Click here to read the article.
A German study of adults from the general population without clinically apparent lung disease, but with low lung function, had significantly increased mortality during a five year period of follow-up. Using spirometry as a low-cost screening tool, investigators found people with lower FEV1 and FVC readings had significantly worse survival. Click here to read the story and access the study.
In today’s open letter to the global asbestos industry, the International Ban Asbestos Secretariat (IBAS) highlights the asbestos lobby’s aggressive actions in Africa and Asia over recent weeks. IBAS works to bring to light the devious means and corrupt practices being used to block national action on banning asbestos. Click here for a review and response of what recently occured… Read more →